BR112015027607A8 - métodos de tratamento de câncer de mama, de câncer da próstata, de câncer carcinoide, de câncer do ovário e de câncer do pulmão em pacientes. - Google Patents
métodos de tratamento de câncer de mama, de câncer da próstata, de câncer carcinoide, de câncer do ovário e de câncer do pulmão em pacientes.Info
- Publication number
- BR112015027607A8 BR112015027607A8 BR112015027607A BR112015027607A BR112015027607A8 BR 112015027607 A8 BR112015027607 A8 BR 112015027607A8 BR 112015027607 A BR112015027607 A BR 112015027607A BR 112015027607 A BR112015027607 A BR 112015027607A BR 112015027607 A8 BR112015027607 A8 BR 112015027607A8
- Authority
- BR
- Brazil
- Prior art keywords
- cancer
- methods
- fgfr1
- patients
- carcinoid
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 6
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 201000011510 cancer Diseases 0.000 title abstract 4
- 206010006187 Breast cancer Diseases 0.000 title abstract 2
- 208000026310 Breast neoplasm Diseases 0.000 title abstract 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 title abstract 2
- 206010033128 Ovarian cancer Diseases 0.000 title abstract 2
- 206010061535 Ovarian neoplasm Diseases 0.000 title abstract 2
- 206010060862 Prostate cancer Diseases 0.000 title abstract 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 title abstract 2
- 208000002458 carcinoid tumor Diseases 0.000 title abstract 2
- 201000005202 lung cancer Diseases 0.000 title abstract 2
- 208000020816 lung neoplasm Diseases 0.000 title abstract 2
- 101100227089 Danio rerio fgfr1a gene Proteins 0.000 abstract 7
- 230000004927 fusion Effects 0.000 abstract 3
- 230000002018 overexpression Effects 0.000 abstract 3
- 101150019331 FGF2 gene Proteins 0.000 abstract 2
- 101150025764 FGFR3 gene Proteins 0.000 abstract 2
- 230000003321 amplification Effects 0.000 abstract 2
- YSFTYXKQUONNFY-NQXPEFQPSA-N fgf2 Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H]1NCCC1)C1=CC=CC=C1 YSFTYXKQUONNFY-NQXPEFQPSA-N 0.000 abstract 2
- 238000003199 nucleic acid amplification method Methods 0.000 abstract 2
- 230000004544 DNA amplification Effects 0.000 abstract 1
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 abstract 1
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 101150016624 fgfr1 gene Proteins 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361818220P | 2013-05-01 | 2013-05-01 | |
| US201361831029P | 2013-06-04 | 2013-06-04 | |
| PCT/US2014/036140 WO2014179448A2 (en) | 2013-05-01 | 2014-04-30 | Methods of treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112015027607A2 BR112015027607A2 (pt) | 2017-12-05 |
| BR112015027607A8 true BR112015027607A8 (pt) | 2018-01-23 |
Family
ID=50928263
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015027607A BR112015027607A8 (pt) | 2013-05-01 | 2014-04-30 | métodos de tratamento de câncer de mama, de câncer da próstata, de câncer carcinoide, de câncer do ovário e de câncer do pulmão em pacientes. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20160067307A1 (https=) |
| EP (1) | EP2991669A2 (https=) |
| JP (1) | JP2016526016A (https=) |
| KR (1) | KR20160003141A (https=) |
| CN (1) | CN105188732A (https=) |
| AU (1) | AU2014259956A1 (https=) |
| BR (1) | BR112015027607A8 (https=) |
| CA (1) | CA2908391A1 (https=) |
| HK (1) | HK1213817A1 (https=) |
| MX (1) | MX2015015115A (https=) |
| RU (1) | RU2015150233A (https=) |
| SG (1) | SG11201508878WA (https=) |
| WO (1) | WO2014179448A2 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2083081A1 (en) | 2005-07-22 | 2009-07-29 | Five Prime Therapeutics, Inc. | Compositions and methods of treating disease with FGFR fusion proteins |
| US8481038B2 (en) | 2010-11-15 | 2013-07-09 | Five Prime Therapeutics, Inc. | Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins |
| CN107823630A (zh) | 2011-11-14 | 2018-03-23 | 戊瑞治疗有限公司 | 治疗癌症的方法 |
| KR102516152B1 (ko) | 2013-08-01 | 2023-03-31 | 파이브 프라임 테라퓨틱스, 인크. | 비푸코실화된 항-ｆｇｆｒ２ｉｉｉｂ 항체 |
| BR112018001438A2 (en) * | 2015-07-24 | 2018-12-04 | Debiopharm International S.A. | gffr expression and susceptibility to a gffr inhibitor |
| MX2018006181A (es) * | 2015-11-23 | 2018-09-24 | Five Prime Therapeutics Inc | Inhibidores de fgfr2 solos o en combinacion con agentes que estimulan el sistema inmunitario en el tratamiento contra el cancer. |
| PL238516B1 (pl) | 2016-06-13 | 2021-08-30 | Univ Wroclawski | Sposób otrzymywania modyfikowanego polipeptydu |
| SG11201906249PA (en) * | 2017-02-06 | 2019-08-27 | Rainier Therapeutics Inc | Methods, compositions, and kits for treatment of cancer |
| WO2018195273A1 (en) * | 2017-04-19 | 2018-10-25 | The Corporation Of Mercer University | Sam-1 protein, composition and methods of use |
| PT3624837T (pt) | 2017-05-16 | 2025-10-01 | Five Prime Therapeutics Inc | Anticorpos anti-fgfr2 em combinação com agentes quimioterapêuticos no tratamento do cancro |
| EP3915576A1 (en) * | 2020-05-28 | 2021-12-01 | Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron | Chimeric antigen receptors specific for p95her2 and uses thereof |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
| DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| US5700637A (en) | 1988-05-03 | 1997-12-23 | Isis Innovation Limited | Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays |
| WO1990006952A1 (fr) | 1988-12-22 | 1990-06-28 | Kirin-Amgen, Inc. | Facteur de stimulation de colonies de granulocytes modifies chimiquement |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| ATE240740T1 (de) | 1991-03-15 | 2003-06-15 | Amgen Inc | Pegylation von polypeptiden |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| US5807522A (en) | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
| ZA9811162B (en) | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
| US6573043B1 (en) | 1998-10-07 | 2003-06-03 | Genentech, Inc. | Tissue analysis and kits therefor |
| CA2348292A1 (en) | 1998-10-30 | 2000-05-11 | Takeda Chemical Industries, Ltd. | Betacellulin protein-containing preparation |
| WO2001075166A2 (en) | 2000-03-31 | 2001-10-11 | Genentech, Inc. | Compositions and methods for detecting and quantifying gene expression |
| CA2407556C (en) | 2000-05-19 | 2011-06-21 | Genentech, Inc. | Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy |
| US20050209310A1 (en) * | 2000-12-22 | 2005-09-22 | Chaplin David J | Methods for modulating tumor growth and metastasis |
| US6900292B2 (en) | 2001-08-17 | 2005-05-31 | Lee-Hwei K. Sun | Fc fusion proteins of human erythropoietin with increased biological activities |
| DK1638941T3 (da) | 2003-05-22 | 2010-10-11 | Abbott Lab | Indazol-, benzisoxazol- og benzisothiazolkinaseinhibitorer |
| WO2006076288A2 (en) | 2005-01-11 | 2006-07-20 | Five Prime Therapeutics, Inc. | Dna constructs for long-term expression of intravascularly injected naked dna |
| EP2083081A1 (en) | 2005-07-22 | 2009-07-29 | Five Prime Therapeutics, Inc. | Compositions and methods of treating disease with FGFR fusion proteins |
| JP2009514879A (ja) * | 2005-11-04 | 2009-04-09 | メルク エンド カムパニー インコーポレーテッド | Ｓａｈａ、カルボプラチン及びパクリタキセルを用いて癌を治療する方法及びその他の併用療法 |
| ES2342646B1 (es) | 2008-06-02 | 2011-04-26 | Institut De Recerca Hospital Universitari Vall Hebron | Metodo de diagnostico de canceres que expresan el receptor her-2 o sus variantes truncadas. |
| KR101910779B1 (ko) * | 2010-11-15 | 2018-10-22 | 파이브 프라임 테라퓨틱스, 인크. | Ｆｇｆｒ１ 세포밖 도메인 조합치료 |
| US8481038B2 (en) * | 2010-11-15 | 2013-07-09 | Five Prime Therapeutics, Inc. | Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins |
| US8951972B2 (en) * | 2010-12-09 | 2015-02-10 | Five Prime Therapeutics, Inc. | FGFR1 extracellular domain combination therapies for lung cancer |
| CN107823630A (zh) * | 2011-11-14 | 2018-03-23 | 戊瑞治疗有限公司 | 治疗癌症的方法 |
-
2014
- 2014-04-30 US US14/785,691 patent/US20160067307A1/en not_active Abandoned
- 2014-04-30 SG SG11201508878WA patent/SG11201508878WA/en unknown
- 2014-04-30 KR KR1020157033756A patent/KR20160003141A/ko not_active Withdrawn
- 2014-04-30 BR BR112015027607A patent/BR112015027607A8/pt not_active IP Right Cessation
- 2014-04-30 RU RU2015150233A patent/RU2015150233A/ru not_active Application Discontinuation
- 2014-04-30 JP JP2016512011A patent/JP2016526016A/ja active Pending
- 2014-04-30 EP EP14729530.7A patent/EP2991669A2/en not_active Withdrawn
- 2014-04-30 HK HK16101949.2A patent/HK1213817A1/zh unknown
- 2014-04-30 CA CA2908391A patent/CA2908391A1/en not_active Abandoned
- 2014-04-30 AU AU2014259956A patent/AU2014259956A1/en not_active Abandoned
- 2014-04-30 WO PCT/US2014/036140 patent/WO2014179448A2/en not_active Ceased
- 2014-04-30 MX MX2015015115A patent/MX2015015115A/es unknown
- 2014-04-30 CN CN201480024106.3A patent/CN105188732A/zh active Pending
-
2018
- 2018-01-03 US US15/861,047 patent/US20180280470A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN105188732A (zh) | 2015-12-23 |
| SG11201508878WA (en) | 2015-11-27 |
| WO2014179448A2 (en) | 2014-11-06 |
| HK1213817A1 (zh) | 2016-07-15 |
| EP2991669A2 (en) | 2016-03-09 |
| US20180280470A1 (en) | 2018-10-04 |
| BR112015027607A2 (pt) | 2017-12-05 |
| US20160067307A1 (en) | 2016-03-10 |
| KR20160003141A (ko) | 2016-01-08 |
| JP2016526016A (ja) | 2016-09-01 |
| CA2908391A1 (en) | 2014-11-06 |
| WO2014179448A3 (en) | 2014-12-24 |
| RU2015150233A (ru) | 2017-06-02 |
| MX2015015115A (es) | 2016-06-07 |
| AU2014259956A1 (en) | 2015-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015027607A8 (pt) | métodos de tratamento de câncer de mama, de câncer da próstata, de câncer carcinoide, de câncer do ovário e de câncer do pulmão em pacientes. | |
| MX2024000614A (es) | Anticuerpos anti-fgfr2 combinados con quimioterapia para el tratamiento del cancer. | |
| BR112015016681A8 (pt) | uso de nanopartículas compreendendo paclitaxel e uma albumina, kit, medicamento, composição e forma de dosagem unitária para tratamento de câncer pancreático | |
| AU2018341571A8 (en) | Therapeutic methods relating to HSP90 inhibitors | |
| BR112015009752A2 (pt) | conjugados de anticorpo/fármaco e métodos de uso | |
| BR112015030377A2 (pt) | preparação compreendendo pelo menos um quimioterápico ou substância citotóxica para uso no tratamento de uma doença de um paciente mamífero, preparação e método para tratamento de câncer em um paciente mamífero através de terapia de radiação | |
| BR112015019064A2 (pt) | métodos de tratamento de melanoma | |
| SG10201902664RA (en) | Combination therapy for treating cancer | |
| HK1253507A1 (zh) | 抗 ror1 抗体 | |
| SG10201903112WA (en) | Treatment of cancer using coenzyme q10 combination therapies | |
| BR112015018104A2 (pt) | polipeptídeos de gdf15 modificados, seu uso, composições compreendendo os mesmos e recipiente estéril compreendendo as referidas composições | |
| BR112014031088A2 (pt) | métodos para o tratamento de câncer pancreático usando terapias de combinação que compreendem irinotecano lipossomal | |
| EA201890272A1 (ru) | Axl-специфические конъюгаты антитело-лекарственное средство для лечения рака | |
| BR112021009856A8 (pt) | Terapia para tratamento do câncer com uma administração intratumoral e / ou intravenosa de um mva recombinante que codifica 4-1bbl (cd137l) e / ou cd40l | |
| MX373231B (es) | Agente anticancerigeno. | |
| MX374126B (es) | Conjugados de anticuerpo-fármaco (adc) de duocarmicina que muestran actividad antitumoral in vivo mejorada. | |
| MX392408B (es) | Tratamiento de cáncer gástrico usando terapias de combinación que comprenden irinotecán liposómico oxaliplatino, 5-fluoruracilo (y leucovorina). | |
| BR112015026247A2 (pt) | métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor | |
| BR112016028641A2 (pt) | ?método para tratar câncer? | |
| BR112015033053A2 (pt) | método de tratamento de câncer em um sujeito, método de estimulação do sistema imune em um sujeito, método de aumentar a distribuição de um agente anticâncer a uma célula tumoral, composição, e kit | |
| PH12015501709A1 (en) | Administration of an-activin-a compound to a subject | |
| MX381399B (es) | Formulaciones de coenzima q10 y métodos de uso. | |
| BR112022012867A2 (pt) | Tratamento de câncer com inibidores de cdk12/13 | |
| BR112014029954A2 (pt) | tratamento de tumores sólidos usando coenzima q10 | |
| BR112015026238A2 (pt) | tratamento de câncer com dihidropirazino-pirazinas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law | ||
| B08F | Application fees: dismissal - article 86 of industrial property law |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B08K | Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87) |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2512 DE 26-02-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |